A recent study suggests that GLP-1 medications, commonly used for weight loss, may have little to no effect on the risk of several obesity-related cancers, including thyroid, pancreatic, breast, and kidney cancers. The findings are important as GLP-1 receptor agonists, like Wegovy and Ozempic, are widely prescribed to manage obesity and type 2 diabetes.
The research analyzed data from 48 clinical trials involving more than 94,000 participants. These trials focused on the long-term safety of GLP-1 drugs, particularly regarding cancer risk. The results help clarify the mixed signals from earlier observational studies about the relationship between these drugs and cancer.
The Study on GLP-1 Cancer Risk
Researchers specifically focused on obesity-related cancers, as obesity plays a significant role in the development of several types of cancer. Previous studies had shown conflicting results: some suggested that GLP-1s could lower cancer risk, while others raised concerns about potential risks, particularly for thyroid and pancreatic cancers.
Dr. Cho-Han Chiang, a clinician investigator at Mount Auburn Hospital, led the study. He explained that the primary aim was to determine whether GLP-1 receptor agonists could reduce the risk of obesity-related cancers. These cancers are influenced by excess weight, chronic inflammation, and metabolic issues.
Results: Little to No Impact on Cancer Risk
The study concluded that GLP-1 drugs probably do not affect the risk of thyroid, pancreatic, breast, or kidney cancers. These findings address long-standing safety concerns about GLP-1 receptor agonists. Although early studies raised alarms, the current data from large randomized clinical trials shows no significant evidence supporting these risks.
Dr. Chiang noted that earlier concerns about cancer risk were based on small studies or preclinical data. However, the randomized trial data provides more reliable and comprehensive evidence. The study found no major change in the risk of thyroid, pancreatic, or breast cancers among GLP-1 users.
Could GLP-1s Offer Protective Effects in the Long Term?
While the study found no immediate impact on cancer risk, it acknowledged that long-term effects are still unclear. Dr. Chiang pointed out that GLP-1 receptor agonists improve weight loss and metabolic health, which could potentially reduce the risk of obesity-related cancers over time. However, the follow-up periods in the trials were relatively short, making it difficult to determine the long-term benefits.
Dr. Chiang also emphasized that the current study shows no clear protective effect against cancer risk, but this does not rule out the possibility of such effects over longer durations. He explained that chronic inflammation, insulin resistance, and metabolic disruption are key drivers of obesity-related cancers. By addressing these factors, GLP-1s could, in theory, reduce cancer risk.
Expert Opinions on GLP-1s and Cancer Risk
Several experts in oncology have expressed the need for further research to understand the long-term impact of GLP-1 drugs on cancer. Dr. Anton Bilchik, a surgical oncologist, stated that the study’s short follow-up period (1 to 2 years) may not have been long enough to capture any delayed protective effects.
Dr. Bilchik also raised concerns about the fact that cancer was not the primary focus of the trials. As a result, the data may not have captured all relevant information. Additionally, the impact of long-term obesity on cancer development could complicate the interpretation of these results.
The Future of GLP-1 Medications in Cancer Research
As GLP-1 drugs become more widely prescribed for weight loss and diabetes management, their potential impact on cancer risk will remain a key research topic. Current evidence suggests that these medications do not pose a significant risk for cancers like thyroid, pancreatic, breast, or kidney cancer. However, further studies with longer follow-up periods are needed to better understand the long-term effects of GLP-1 receptor agonists.
Dr. Mir Ali, a bariatric surgeon, pointed out that the duration of weight loss and how long it is maintained may influence cancer risk. As more data becomes available, healthcare professionals will be able to provide more guidance to patients on the risks and benefits of using GLP-1 drugs for weight loss.
